Why Haemonetics Corporation’s (HAE) Stock Is Up 16.52%
As of Thursday, October 08, Haemonetics Corporation’s HAE share price has surged by 16.52%, which has investors questioning if this is right time to sell.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Tudor Pop
Michael Rose
Omar Beirat
Michael Rose
| Share Statistics | HAE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,450.1 | $425.5 | 69% |
|
| Shares Out (Mil) | 45.7 | 40.4 | 45% |
|
| Institutional Ownership | 98.8% | 83.0% | 82% |
|
| Float (Mil) | 44.9 | 34.7 | 44% |
|
| Beta | 0.61 | 0.85 | 35% |
|
| Avg Daily Volume (000s) | 587 | 287 | 61% |
|
| Price Change (52-week) |
137.9% | 65.2% | 97% |
|
| Growth | HAE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.9% | 11.8% | 54% |
|
| Net Income (5yr) | 4.1% | (5.5%) | 46% |
|
| EPS (5yr) | 5.8% | 10.7% | 40 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (26.2%) | (15.6%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | $1.291 | $5.309 | $5.777 | |
| Month Ago EPS | $1.291 | $5.309 | $5.777 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $1.274 | $5.217 | $5.626 | |
| Year/Year Chg | 79.3% | 159.0% | 216.2% | |
| Financials | HAE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,352 | $128 | 54% |
|
| Net Income (TTM) (Mil) | $96 | ($9) | 60% |
|
| EPS (TTM) | $2.071 | ($0.400) | 72% |
|
| Operating Cash Flow (TTM) (Mil) | $328 | ($2) | 66% |
|
| Net Cash Flow (TTM) (Mil) | ($70) | $1 | 17% |
|
| Long-Term Debt (Q1) (Mil) | $1,169 | $23 | 68% |
|
| Enterprise Value (Q1) (Mil) | $6,278 | $399 | 66% |
|
| Valuation | HAE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.51 | 2.49 | 85% |
|
| P/E | 58.2 | 28.5 | 88% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 10.0 | 1.5 | 94% |
|
| Ratios | HAE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 59.3% | 59.3% | 72% |
|
| Net Margin | 7.1% | (6.9%) | 54% |
|
| ROA | 4.0% | (11.8%) | 66% |
|
| ROE | 11.2% | (10.1%) | 60% |
|
| Liabilities to Assets | 64.6% | 47.2% | 60% |
|
| F-Score | 7 | 4 | 82% |
|
Haemonetics Corporation did not pass any screens on 10/29/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors